SUTRO BIOPHARMA, INC. (STRO) Return on equity 2018–2024
SUTRO BIOPHARMA, INC. (STRO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-510.0%FY2024 · since FY2018: -26.8% → -510.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -510.0% | -438.6 pp |
| FY2023 | -71.4% | -16.4 pp |
| FY2022 | -54.9% | -13.1 pp |
| FY2021 | -41.8% | -32.1 pp |
| FY2020 | -9.7% | +112.2 pp |
| FY2019 | -121.9% | -95.1 pp |
| FY2018 | -26.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More STRO financial trends
STRO RevenueSTRO Net incomeSTRO Net marginSTRO Gross profitSTRO Gross marginSTRO Operating incomeSTRO Operating marginSTRO Operating cash flowSTRO Free cash flowSTRO Capital expendituresSTRO Stock buybacksSTRO Dividends paidSTRO Total assetsSTRO Total liabilitiesSTRO Shareholders’ equitySTRO overview →